Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1 Mesothelioma, Malignant 1 Leukemia, Myeloid, Acute 1 Inflammatory Breast Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma of Lung 1

Interventions

Cisplatin 28 Pemetrexed 22 Gemcitabine 10 Nivolumab 9 Carboplatin 9 pembrolizumab 8 tremelimumab 5 durvalumab 5 atezolizumab 5 Radiotherapy 5 Doxorubicin 4 Chemotherapy, Adjuvant 4 Vinorelbine 3 Ipilimumab 3 Bortezomib 3 Bevacizumab 3 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 sodium thiosulfate 2 sargramostim 2 niraparib 2 nintedanib 2 liposomal doxorubicin 2 lenvatinib 2 defactinib 2 cemiplimab 2 cediranib 2 amatuximab 2 Trabectedin 2 Neoadjuvant Therapy 2 Mitomycin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Mesothelioma, Malignant × bemcentinib × Clear all

NCT03654833 2023-03-14

MiST

University of Leicester

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡